Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C18H20FN3O4
CAS Number:
Molecular Weight:
361.37
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
SMILES string
CC1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(O)=O
InChI key
GSDSWSVVBLHKDQ-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
ofloxacin, ofloxacin
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Looking for similar products? Visit Product Comparison Guide
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Ofloxacin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
Also, for use with USP monographs such as:
- Ofloxacin Tablets
- Ofloxacin Ophthalmic Solution
- Levofloxacin
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Storage Class
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mahesh D Chavanpatil et al.
International journal of pharmaceutics, 316(1-2), 86-92 (2006-03-29)
Oral sustained release gastroretentive dosage forms offer many advantages for drugs having absorption from upper gastrointestinal tract and improve the bioavailability of medications that are characterized by a narrow absorption window. A new gastroretentive sustained release delivery system was developed
J P Monk et al.
Drugs, 33(4), 346-391 (1987-04-01)
Ofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid. It is an orally administered broad spectrum antibacterial drug active against most Gram-negative bacteria, many Gram-positive bacteria and some anaerobes. Ciprofloxacin is the only other
G A Gates
The Pediatric infectious disease journal, 20(1), 104-107 (2001-02-15)
To assess the safety of topical agents in the middle ear, animal studies were reviewed. Compared with aminoglycoside-containing preparations, which caused significant loss of hair cells in the basal turn of the cochlea, ofloxacin caused no loss of hair cells
C D Bluestone
The Pediatric infectious disease journal, 20(1), 111-115 (2001-02-15)
The safety and efficacy of ototopical preparations, such as ofloxacin, in the treatment of CSOM in infants and children do not currently have approval by the FDA even though ofloxacin is FDA-approved for treatment of CSOM that occurs in adults.
S M Traeger et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 21(6), 1504-1506 (1995-12-01)
We describe four patients who had seizures while receiving ofloxacin; no other causes were evident. Common factors among all patients included advanced age and use of a high-dose regimen. The renal insufficiency of three patients and the timing of the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service